Key result
Dronedarone reduces mortality and morbidity in patients with high-risk atrial fibrillation, but may be unsafe in those with severe heart failure.
Why the study?
Does dronedarone improve safety and effectiveness in patients with atrial fibrillation?
Does dronedarone improve safety and effectiveness in patients with atrial fibrillation?
Dronedarone is an effective antiarrhythmic for maintaining sinus rhythm in atrial fibrillation, reducing morbidity and mortality in high-risk patients, though it may be unsafe in severe heart failure.
Supports restricted dronedarone use in high-risk AF; leaves open safety and selection questions in severe heart failure.
Amiodarone is the most effective antiarrhythmic drug for maintaining sinus rhythm for patients with atrial fibrillation. Extra-cardiac side effects have been a limiting factor, especially during chronic use, and may offset its benefits. Dronedarone is a noniodinated benzofuran derivative of amiodarone that has been developed for the treatment of atrial fibrillation and atrial flutter. Similar to amiodarone, dronedarone is a potent blocker of multiple ion currents, including the rapidly activating delayed-rectifier potassium current, the slowly activating delayed-rectifier potassium current, the inward rectifier potassium current, the acetylcholine activated potassium current, peak sodium current, and L-type calcium current, and exhibits antiadrenergic effects. It has been studied for maintenance of sinus rhythm and control of ventricular response during episodes of atrial fibrillation. Dronedarone reduces mortality and morbidity in patients with high-risk atrial fibrillation, but may be unsafe in those with severe heart failure. This article will review evidence of safety and effectiveness of dronedarone in patients with atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2009) conducted a review in Atrial fibrillation. Dronedarone was evaluated. Dronedarone reduces mortality and morbidity in patients with high-risk atrial fibrillation, but may be unsafe in those with severe heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: